← Leaderboards
Barbara Savoldo
Baylor College Of Medicine
$8,193,565
Attributed
$10,690,563
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$10,690,563 · 6
By mechanism
R01$6,900,803 · 3
U01$3,221,135 · 1
R21$568,625 · 2
Top collaborators
- Catherine Mary Bollard5 shared
- Conrad Russell Young Cruz5 shared
- Richard J Jones5 shared
- Jianguo Wen1 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Helen E Heslop$25,308,937
- Cliona M Rooney$13,445,584
- Stephen Gottschalk$13,145,706
- Malcolm K Brenner$13,204,649
- Ann M. Leen$2,736,030
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsIn VivoRelapseCellsT-LymphocyteImmunotherapyTumorCytotoxic T-LymphocytesImmuneSiteRefractoryAntigensReceptorBaseResponseNeoplastic CellMediatingAntibodiesChemokineCytokineAutologousAdoptive TransferCancer CellHodgkin Disease
Grant awards (23)
Tailoring CAR T cell therapy for Hodgkin Lymphoma$599,281
R01 · FY2024 · CA · contact PI
Tailoring CAR T cell therapy for Hodgkin Lymphoma$619,470
R01 · FY2023 · CA · contact PI
Enhancing cell therapy for brain tumors$636,818
U01 · FY2022 · CA
Tailoring CAR T cell therapy for Hodgkin Lymphoma$622,000
R01 · FY2022 · CA · contact PI
Enhancing cell therapy for brain tumors$636,455
U01 · FY2021 · CA
Tailoring CAR T cell therapy for Hodgkin Lymphoma$634,693
R01 · FY2021 · CA · contact PI
Enhancing cell therapy for brain tumors$636,807
U01 · FY2020 · CA
Tailoring CAR T cell therapy for Hodgkin Lymphoma$634,693
R01 · FY2020 · CA · contact PI
Enhancing cell therapy for brain tumors$636,799
U01 · FY2019 · CA
Enhancing cell therapy for brain tumors$674,256
U01 · FY2018 · CA
Enhancement of stem cell transplants using CAR.CD30-redirected T lymphocytes$447,090
R01 · FY2017 · HL · contact PI
Enhancement of stem cell transplants using CAR.CD30-redirected T lymphocytes$447,090
R01 · FY2016 · HL · contact PI
Enhancement of stem cell transplants using CAR.CD30-redirected T lymphocytes$440,384
R01 · FY2015 · HL · contact PI
Enhancement of stem cell transplants using CAR.CD30-redirected T lymphocytes$452,675
R01 · FY2014 · HL · contact PI
Enhancement of stem cell transplants using CAR.CD30-redirected T lymphocytes$439,742
R01 · FY2013 · HL · contact PI
Chimeric T Cell for Therpay of Hodgkin Disease$308,958
R01 · FY2012 · CA · contact PI
Chimeric T Cell for Therpay of Hodgkin Disease$308,958
R01 · FY2011 · CA · contact PI
Myeloma stem cell and cancer testis antigens$162,293
R21 · FY2011 · CA
Chimeric T Cell for Therpay of Hodgkin Disease$318,513
R01 · FY2010 · CA · contact PI
Chimeric T Cell for Therpay of Hodgkin Disease$318,513
R01 · FY2009 · CA · contact PI
Chimeric T Cell for Therpay of Hodgkin Disease$308,743
R01 · FY2008 · CA · contact PI
Improving Function and Persistence of Chimeric T Cells$256,332
R21 · FY2006 · AI · contact PI
Improving Function and Persistence of Chimeric T Cells$150,000
R21 · FY2005 · AI